Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4393-4407

  Karnaoukhova, Larissa ^a   Moffat, Joyce ^a   Martins, Heidi ^b   Glickman, Barry ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CLINICAL ARTICLE; CYTOGENETICS; CYTOTOXICITY; DNA DAMAGE; DNA SEQUENCE; DNA SYNTHESIS INHIBITION; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC MARKER; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, SMALL CELL; CLONE CELLS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LUNG NEOPLASMS; MALE; MUTAGENESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 0030865676     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Smith, M. A., Rubinstein, L., and Ungerleider, R. S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol., 23: 86-98, 1994.
2. Domer, P. H., Head, D. R., Renganathan, N., Raimondi, S. C., Yang, E., and Atlas, M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4:11). Leukemia (Baltimore), 9: 1305-1312, 1995.
3. Bernard, O. A., and Berger, R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer, 13: 75-85, 1995.
4. Rowley, J. D. Rearrangements involving chromosome band 11q23 in acute leukemia. Semin. Cancer Biol., 4: 377-385, 1993.
5. Gu, Y., Alder, H., Nakamura, T., Schichman, S. A., Prasad, R., Canaani, O., Saito, H., Croce, C. M., and Canaani, E. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res., 54: 2327-2330, 1994.
6. Schichman, S. A., Caligiuri, M. A., Strout, M. P., Carter, S. L., Gu, Y., Canaani, E., Bloomfield C. D., and Croce, C. M. All-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res., 54: 4277-4280, 1994.
7. Gu, Y., Cimino, G., Alder, H., Znakamura, T., Prasad, R., Canaani, O., Moir, D., Jones, C., Nowell, P., Croce, C., and Canaani, E. The (4:11)(q21:q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc. Natl. Acad. Sci. USA, 89: 10464-10468, 1992.
8. Felix, C. A., Lange, B. J., Hosler, M. R., Fertala, J., and Bjornsti, M. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res., 55: 4287-4292, 1995.
9. Negrini, M., Felix, C. A., Martin, C. Lange, B. J., Nakamura, T., Canaani, E., and Croce, C. M. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9:11) chromosome translocation in acute myeloid leukemia. Cancer Res., 53: 4489-4492, 1993.
10. Liu., L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
11. Anderson, R. D., and Berger, N. A. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res., 309: 109-142, 1994.
12. Ferguson, L. R., and Baguley, B. C. Topoisomerase II enzymes and mutagenicity. Environ. Mol. Mutagen., 24: 245-261, 1994.
13. Cole, J., and Skopek, T. R. ICPEM Committee on spontaneous mutation. Working paper 3: somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutat. Res., 304: 33-105, 1994.
14. Cariello, N. F., Craft, T. R., Vrieling, H., van Zeeland, A. A., Adams, T., and Skopek, T. R. Human HPRT mutant database: software for data entry and retrieval. Environ. Mol. Mutagen., 20: 81-83, 1992.
15. Branda, R. F., O'Neill, J. P., Sullivan, L. M., and Albertini, R. J. Factors influencing mutation at the hprt locus in T lymphocytes: women treated for breast cancer. Cancer Res., 51: 6603-6607, 1991.
16. Tates, A. D., van Dam, F. J., Natarajan, A. T., Zwinderman, A. H., and Osanto, S. Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat. Res., 307: 293-306, 1994.
17. Hirota, H., Kubota, M., Hashimoto, H., Adachi, S., Matsubara, K., Kuwakado, K., Akiyama, Y., Tsutsui, T., and Mikawa, H. Analysis of hprt gene mutation following anti-cancer treatment in pediatric patients with acute leukemia. Mutat. Res., 319: 113-120, 1993.
18. Ammenheuser, M. M., Ward, J. B., Jr., Whorton, E. B., Jr., Killian, J. M., and Legator, M. S. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutat. Res., 204: 509-520, 1988.
19. Caggana, M., Liber, H. L., Mauch, P. M., Coleman, C. N., and Kesley, K. T. In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. Environ. Mol. Mutagen., 18: 6-13, 1991.
20. Dempsey, J. L., Seshadri, R. S., and Morley, A. A. Increased mutation frequency following treatment with cancer chemotherapy. Cancer Res., 45: 2873-2877, 1985.
21. Curry, J., Skandalis, A., Holcroft, J., de Boer, J., and Glickman, B. Coamplification of hprt cDNA and γ T-cell receptor sequences from 6-thioguanine resistant human T-lymphocytes. Mutat. Res., 288: 269-275, 1993.
22. Gibbs, R. A., Nguyen, P., Edwards, A., Civitello, A. B., and Caskey, C. T. Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyl-transferase gene in Lesch-Nyhan families. Genomics. 7: 235-244, 1990.
23. Steingrimsdottir, H., Rowley, G., Dorado, G., Cole, J., and Lehmann, A. R. Mutations which alter splicing in the human hypoxanthine-guanine phosphoribosyltransferase gene. Nucleic Acids Res., 6: 1201-1218, 1992.
24. Manjanatha, M. G., Lindsey, L. A., Mittelstaedt, R. A., and Heflich, R. H. Low hprt mRNA levels and multiple hprt mRNA species in 6-thioguanine-resistant Chinese hamster cell mutants possessing nonsense mutations. Mutat. Res., 308: 65-75, 1994.
25. Curry, J., Rowley, G., Saddi, V., Beare, D., Cole, J., and Glickman, B. Determination of hprt mutant and mutation frequencies and the molecular characterization of human derived in vivo T-lymphocyte mutants. Environ. Mol. Mutagen., 25: 169-179, 1995.
26. Skandalis, A., Ford, B. N., and Glickman, B. W. Strand bias in mutation involving 5-methylcytosine deamination in the human hprt gene. Mutat. Res., 314: 21-26, 1994.
27. Reid, T. M., and Loeb, L. A. Tandem double CC→TT mutations are produced by reactive oxygen species. Proc. Natl. Acad. Sci. USA, 90: 3904-3907, 1993.
28. McGregor, W. G., Chen, R. H., Lukash, L., Maher, V. M., and McCormick, J. J. Cell cycle-dependent strand bias for UV-induced mutations in the transcribed strand of excision repair-proficient human fibroblasts but not in repair-deficient cells. Mol. Cell Biol., 11: 1927-1934, 1991.
29. Perera, F. R., Motzer, R. J., Tang, D., Reed, E., Parker, R., Warburton, D., O'Neill, P., Albertini, R., Bigbee, W. L., Jensen, R. H., Santella, R., Tsai, W-Y., Simon-Cereijido, G., Randall, C., and Bosl, G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res., 52: 3558-3565, 1992.
30. Dubeau, H., Zazi, W., Baron, C., and Messing, K. Effects of lymphocyte subpopulations on clonal assay of HPRT mutants: occupational exposure to cytostatic drugs. Mutat. Res., 321: 147-157, 1994.
31. Branda, R. F., Sullivan, L. M., O'Neill, J. P., Falta, M. T., Nicklas, J. A., Hirsch, B., Vacek, P. M., and Albertini, R. J. Measurement of HPRT mutant frequencies in T-lymphocytes from healthy human populations. Mutat. Res., 285: 267-279, 1993.
32. O'Neill, J. P., Nicklas, J. A., Hunter, T. C., Batson, O. B., Allegretta, M., Falta, M. T., Branda, R. F., and Albertini, R. J. The effect of T-lymphocyte 'clonality' on the calculated hprt mutation frequency occurring in vivo in humans. Mutat. Res., 313: 215-225, 1994.
33. Morley, A. A. The estimation of in vivo mutation rate and frequency from samples of human lymphocytes. Mutat. Res., 357: 167-176, 1996.
34. Bogen, K. T. Reassessment of human peripheral T-lymphocyte lifespan deduced from cytogenetic and cytotoxic effects of radiation. Int. J. Radiat. Biol., 64: 195-204, 1993.
35. Maraschin, J., Dutrillaux, B., and Aurias, A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int. J. Cancer, 46: 808-812, 1990.
36. Greco, F. A. Etoposide: seeking the best dose and schedule. Semin. Oncol., 19 (Suppl. 14): 59-63, 1992.
37. Singh, B., and Gupta, R. S. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res., 43: 577-584, 1983.
38. Ashby, J., Tinwell, H., Glover, P., Poorman-Allen, P., Krehl, R., Callander, R. D., and Clive, D. Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. Environ. Mol. Mutagen., 24: 51-60, 1994.
39. Tominaga, K., Shinkai, T., Saijo, N., Nakajima, T., Ochi, H., and Suemasu, K. Cytogenetic effects of etoposide (VP-16) on human lymphocytes, with special reference to the relation between sister chromatid exchange and chromatid breakage. Jpn. J. Cancer Res., 77: 385-391, 1986.
40. Walker, P. R., Smith, C., Youdale, T., Leblanc, J., Whitfield, J. F., and Sikorska, M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res., 51: 1078-1085, 1991.
41. Mizumoto, K., Rothman, R. J., and Farber, J. L. Programmed cell death (apoptosis) of mouse fibroblasts is induced by the topoisomerase II inhibitor etoposide. Mol. Pharmacol., 46: 890-895, 1994.
42. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y., and Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (Baltimore), 9: 1013-1024, 1995.
43. Pette, M., Gold, R., Pette, D. F., Hartung, H. P., and Toyka, K. V. Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology, 30: 59-69, 1995.
44. Fournel, S., Genestier, L., Rouault, J. P., Lizard, G., Flacher, M., Assossou, O., and Revillard, J. P. Apoptosis without decrease of cell DNA content. FEBS Lett., 367: 188-192, 1995.
45. Li, X., Gong, J., Feldman, E., Seiter, K., Raganos, F., and Darzynkiewicz, Z. Apoptotic cell death during treatment of leukemia. Leuk. Lymphoma, 13 (Suppl. 1): 65-70, 1994.
46. Matsubara, K., Kubota, M., Adachi, S., Kuwakado, K., Hirota, H., Wakazono, Y., Akiyama, Y., and Mikawa, H. Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo. Eur. J. Haematol., 52: 47-52, 1994.
47. Nicklas, J. A., O'Neill, J. P., Hunter, T. C., Falta, M. T., Lippert, M. J., Jacobson-Kram, D., Williams, J. R., Albertini, R. J. In vivo ionizing irradiations produce deletions in the hprt gene of human T-lymphocytes. Mutat. Res., 250: 383-396, 1991.
48. Edwards, A., Voss, H., Rice, P., Civitello, A., Stegemann, J., Schwager, C., Zimmermann, J., Erfle, H., Caskey, C. and Ansorge, W. Automated DNA sequencing of the human HPRT locus. Genomics, 6: 593-608, 1990.
49. Curry, J., Khaidakov, M., da Cruz, A., Karnaoukhova, L., Kusser, W. C., de Boer, J., Moffat, J., and Glickman, B. W. Mutational specificity and cancer chemoprevention. J. Cell Biochem., 64: 1-9, 1996.
50. - mutations in individuals exposed to ionizing radiation in Goiania, Brazil. Environ. Mol. Mutagen., 29: 107-116, 1997.
51. Skandalis, A., Curry, J., O'Neill, Nicklas, J. A., Albertini, R., Glickman, B. W. Analysis of point mutations in the hprt gene of cancer patients treated with radioimmunoglobulin therapy. Environ. Mol. Mutagen., 26: 213-217, 1995.
52. Pluth, J. M., Nicklas, J. A., O'Neill, J. P., and Albertini, R. J. Increased frequency of specific genomic deletions resulting from in vitro malathion exposure. Cancer Res., 56: 2393-2399, 1996.
53. Berger, N. A., Chatterjee, S., Schmotzer, J. A., and Helms, S. R. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc. Natl. Acad. Sci. USA, 88: 8740-8743, 1991.
54. Han, Y., Finley Austin M. J., Pommier, Y., and Povirk, L. F. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J. Mol. Biol., 229: 52-66, 1993.
55. Chen, C. L., Fuscoe, J. C., Liu, Q., and Relling, M. V. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood, 88: 2210-2218, 1996.
56. Fuscoe, J. C., Zimmermann, L. J., Harrington-Brock, K., Burnette, L., Moore, M. M., Nicklas, J. A., O'Neill, J. P., and Albertini, R. J. V(D)J recombinase-mediated deletion of the hprt gene in T-lymphocytes from adult humans. Mutat. Res., 283: 13-20, 1992.
57. Jansen, J. G., Vrieling, H., van Teijlingen, C. M., Mohn, G. R., Tates, A. D., and van Zeeland, A. A. Marked differences in the role of O6-alkylguanine in hprt mutagenesis in T lymphocytes of rats exposed in vivo to ethylmethanesulfonate, N-(2-hydroxyethyl)-N-nitrosourea, or N-ethyl-N-nitrosourea. Cancer Res., 55: 1875-1882, 1995.
58. Hartmann, A., Rosanelli, G., Blaszyk, H., Cunningham, J. M., McGovern, R. M., Schroeder, J. J., Schaid, D. J., Kovach, J. S., and Sommer, S. S. Novel pattern of p53 mutation in breast cancers from Austrian women. J. Clin. Invest., 95: 686-689, 1995.
59. Johnson, B. E., and Kelley, M. J. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest, 103 (Suppl.): 1S-3S, 1993.
60. Cherpillod, P., and Amstad, P. A. Benzo(a)pyrene-induced mutagenesis of p53 hot-spot codons 248 and 249 in human hepatocytes. Mol. Carcinog., 13. 15-20, 1995.
61. Vrieling, H., Thijssen, J. C. P., Rossi, A. M., van Dam F. J., Natarajan, A. T., Tates, A. D., and van Zeeland, A. A. Enhanced hprt mutant frequency but no significant difference in mutalion spectrum between a smoking and a non-smoking human population. Carcinogenesis (Lond.), 13: 1625-1631, 1992.
62. Burkhart-Schultz, K. J., Thompson, C. L., and Jones, I. M. Spectrum of somatic mutation at the hypoxanthine phosphoribosyltransferase (hprt) gene of healthy people. Carcinogenesis (Lond.), 17: 1871-1883, 1996.